Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Refractory C. Difficile and Colitis
NCT03268213Phase 1Completed
- Sponsor
- Stony Brook University
- Start
- Nov 2013
- Primary completion
- Feb 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in Clostridioides difficile infection (CDI), ulcerative colitis (UC) and indeterminate colitis (IC), sponsored by Stony Brook University. Primary endpoint: Number of participants with treatment-related adverse events at 1 year. Started Nov 2013; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Clostridioides difficile infection (CDI)ulcerative colitis (UC)indeterminate colitis (IC)
Beyond the preview
Go deeper on NCT03268213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03268213.